Peer-reviewedCC BYBiomedicines
Lipoprotein(a) After Myocardial Infarction: Residual Risk, Measurement, and the Unresolved Therapeutic Question
- 1Doctoral School of Medicine, “Victor Babeș” University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania; (A.G.); (S.A.); (D.R.); (B.-F.B.)
- 2Department V—Internal Medicine 1, “Victor Babeș” University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania; (T.P.); (M.A.)
Related
- Simultaneous two-vessel occlusion causing ST-segment elevation myocardial infarction associated with elevated lipoprotein (a): A case report
- Prognostic Value of Serum Lipoprotein(a) Levels in Japanese Patients With ST-Segment Elevation Myocardial Infarction
- High Lipoprotein(a) Is a Predictor of Adverse Events and Heart Failure in Patients With Acute Myocardial Infarction
- Elevated Lipoprotein(a) Predicts Recurrent Myocardial Infarction in Diabetic Patients Following Acute Coronary Syndromes
- Estimated small dense low-density lipoprotein cholesterol and incident myocardial infarction in patients undergoing dialysis: a nationwide cohort study.
BibTeX
@article{gogan2026lipoproteina,
title = {{Lipoprotein(a) After Myocardial Infarction: Residual Risk, Measurement, and the Unresolved Therapeutic Question}},
author = {Alexandra Gogan and Samuel Ardelean and Daniel Rus and Florina Rozina Căruntu and Bogdan-Flaviu Buz and Tudor Parvanescu and Minodora Andor},
journal = {Biomedicines},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13702357},
note = {CC BY},
}
RIS
TY - JOUR
TI - Lipoprotein(a) After Myocardial Infarction: Residual Risk, Measurement, and the Unresolved Therapeutic Question
AU - Alexandra Gogan
AU - Samuel Ardelean
AU - Daniel Rus
AU - Florina Rozina Căruntu
AU - Bogdan-Flaviu Buz
AU - Tudor Parvanescu
AU - Minodora Andor
PY - 2026
DA - 2026/10/01
JO - Biomedicines
UR - https://europepmc.org/article/PMC/PMC13702357
SN - 2227-9059
ER -